PE20061199A1 - Composicion conteniendo derivados de cianopirrolidina para preparaciones farmaceuticas solidas, preparacion farmaceutica solida conteniendo la composicion y proceso para producir la preparacion farmaceutica solida - Google Patents
Composicion conteniendo derivados de cianopirrolidina para preparaciones farmaceuticas solidas, preparacion farmaceutica solida conteniendo la composicion y proceso para producir la preparacion farmaceutica solidaInfo
- Publication number
- PE20061199A1 PE20061199A1 PE2006000103A PE2006000103A PE20061199A1 PE 20061199 A1 PE20061199 A1 PE 20061199A1 PE 2006000103 A PE2006000103 A PE 2006000103A PE 2006000103 A PE2006000103 A PE 2006000103A PE 20061199 A1 PE20061199 A1 PE 20061199A1
- Authority
- PE
- Peru
- Prior art keywords
- solid pharmaceutical
- halogen
- composition
- pharmaceutical preparation
- hydroxyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title 3
- 239000007787 solid Substances 0.000 title 3
- 239000000203 mixture Substances 0.000 title 2
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical group [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 abstract 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 abstract 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES HALOGENO, HIDROXILO, ALCOXI C1-C5, ALQUILO C1-C5, ENTRE OTROS; R2 ES H, HALOGENO, HIDROXILO, ALCOXI C1-C5, ENTRE OTROS; R3 Y R4 SON CADA UNO H, HALOGENO, HIDROXILO, ALCOXI C1-C5, ENTRE OTROS; X ES O, S; Y ES -CR5R6-; R5 Y R6 SON CADA UNO H, HALOGENO, ALQUILO C1-C10 SUSTITUIDO O NO, ENTRE OTROS; W ES H, ACILO DERIVADO DE AMINOACIDOS QUE OCURREN NATURALMENTE, ENTRE OTROS; Z ES H, ALQUILO C1-C10 SUSTITUIDO O NO CON HALOGENO, HIDROXILO HIDROXIALQUILO C1-C5, ENTRE OTROS. UN COMPUESTO PREFERIDO ES: SAL DE ACIDO BENCENOSULFONICO DE (2S,4S)-2-CIANO-4-FLUORO-1-[(2-HIDROXI-1,1-DIMETIL)ETILAMINO]ACETILPIRROLIDINA. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN ESTABILIZANTE SELECCIONADO ENTRE AZUCARES Y ALCOHOLES DE AZUCAR QUE REDUCE LA DESCOMPOSICION DEL COMPUESTO, Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA DIPEPTIDILPEPTIDASA IV (DPPIV) UTILES EN EL TRATAMIENTO DE DIABETES TIPO 2
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005022193A JP2008024592A (ja) | 2005-01-28 | 2005-01-28 | シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20061199A1 true PE20061199A1 (es) | 2006-11-18 |
Family
ID=36570928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000103A PE20061199A1 (es) | 2005-01-28 | 2006-01-24 | Composicion conteniendo derivados de cianopirrolidina para preparaciones farmaceuticas solidas, preparacion farmaceutica solida conteniendo la composicion y proceso para producir la preparacion farmaceutica solida |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2008024592A (es) |
AR (1) | AR052197A1 (es) |
DO (1) | DOP2006000019A (es) |
PE (1) | PE20061199A1 (es) |
TW (1) | TW200637815A (es) |
WO (1) | WO2006080412A2 (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
GB0115517D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
AU2002360732A1 (en) * | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
HUP0200849A2 (hu) * | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
EA007613B1 (ru) * | 2002-08-29 | 2006-12-29 | Тайсо Фармасьютикал Ко., Лтд. | Бензолсульфонатная соль (2s,4s)-1-циано-4-фтор-1-[(2-гидрокси-1,1-диметил)этиламино]ацетилпирролидина |
HU227684B1 (en) * | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
RU2766487C2 (ru) * | 2004-01-20 | 2022-03-15 | Новартис Аг | Композиция и способ прямого прессования |
-
2005
- 2005-01-28 JP JP2005022193A patent/JP2008024592A/ja active Pending
-
2006
- 2006-01-20 WO PCT/JP2006/301258 patent/WO2006080412A2/en not_active Application Discontinuation
- 2006-01-24 DO DO2006000019A patent/DOP2006000019A/es unknown
- 2006-01-24 AR ARP060100263A patent/AR052197A1/es not_active Application Discontinuation
- 2006-01-24 PE PE2006000103A patent/PE20061199A1/es not_active Application Discontinuation
- 2006-01-25 TW TW095102875A patent/TW200637815A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006080412A2 (en) | 2006-08-03 |
AR052197A1 (es) | 2007-03-07 |
WO2006080412A3 (en) | 2006-09-21 |
JP2008024592A (ja) | 2008-02-07 |
DOP2006000019A (es) | 2006-07-15 |
TW200637815A (en) | 2006-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA109774C2 (uk) | Кристалічні форми саксагліптину та процес його одержання (варіанти) | |
AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
PE20020707A1 (es) | Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c | |
BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
UY27317A1 (es) | Resolución de sal quiral | |
NO20081212L (no) | Xantinderivater som selektive HM74A agonister | |
BR122017021516B8 (pt) | processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia | |
BR0317268A (pt) | Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos | |
RS20050939A (en) | Pyrido/2,1-a/isoquinoline derivatives as dpp-iv inhibitors | |
PE20040450A1 (es) | Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa | |
BR0312975A (pt) | Forma cristalina de agonista de receptor adrenérgico ß2 | |
BRPI0314325B8 (pt) | derivados de aza-bicicloalquila, seu uso, seu processo de preparação e composição farmacêutica que os compreende | |
BRPI0520252A2 (pt) | método de desacilar sucralose-6-éster | |
TW200517389A (en) | Biaryloxymethylarenecarboxylic acids | |
BR0308993A (pt) | Métodos para desacilação aquosa estabilizada por tampão | |
PE20060240A1 (es) | Derivados de pirimidina para tratar el crecimiento celular anomalo | |
BR0313831A (pt) | Sais benzenossulfonato de derivados de 4-flúor-2-cianopirrolidina | |
AR087302A1 (es) | Derivados aza heterociclicos sustituidos | |
Lecerclé et al. | Bacterial transferase MraY inhibitors: Synthesis and biological evaluation | |
ES2206078A1 (es) | Proceso para la preparacion de gabapentina. | |
BRPI0512522A (pt) | processo para a preparação de sal de sódio de esomeprazol, composto, formulação farmacêutica, e, método de tratamento | |
HUP0002754A2 (hu) | (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanol-hemiszulfát, eljárás előállítására, ezt tartalmazó gyógyszerkészítmény, valamint intermedierek | |
PE20061199A1 (es) | Composicion conteniendo derivados de cianopirrolidina para preparaciones farmaceuticas solidas, preparacion farmaceutica solida conteniendo la composicion y proceso para producir la preparacion farmaceutica solida | |
PE20030617A1 (es) | Aminoacidos, procedimiento para su preparacion y medicamentos que los contienen | |
PT1257552E (pt) | Derivados de xantina, intermediarios e aplicacao ao tratamento de osteoporose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FX | Voluntary withdrawal |